**International Journal of Pharmacy and Herbal Technology**

**e-ISSN:** 2583-8962 Vol. 3, Issue 1 (January – April, 2025) pp: (3825-3841)

# Comprehensive Review on Gastroretentive Drug Delivery System

Samarth G. Patil *, Shirish B. Nagansurkar, Sanjay K. Bais

Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India

*Corresponding Author: samarthpatil334@gmail.com

*Received Date: February 02,2025; Published Date: April 03,2025*

## Abstract

*The purpose of gastroretentive systems for drug delivery (GRDDS) is to enhance the pharmacotherapy of medications that have a limited window for absorption in the upper digestive tract. This study offers a thorough analysis of several gastroretentive strategies, such as expandable, high-density, mucoadhesive, and floating system. The benefits, drawbacks, and mechanism of stomach retention of each approach are examined in light of stability, patient compliance, and drug release properties. The potential of formulation design innovations, like the use of polymers and developments in biodegradable systems, to improve the effectiveness and regularity of drug release is investigated. The purpose of gastroretentive systems for drug delivery (GRDDS) is to increase the bioavailability of medications that are absorbed mostly in the upper part of the gut by extending the retention of dose forms in the stomach. Drugs with limited availability windows, those that break down in the gastrointestinal tract, or those that are poorly soluble in intestinal pH benefit from these systems. Each type of GRDDS—floating, bioadhesive, swellable, or expandable—uses a different method to guarantee long-term stomach retention. The effectiveness and predictability of GRDDS have been further enhanced by recent developments in formulation technologies, such as fresh polymers and synthetic materials, which make them attractive choices for delivering medications to the upper intestine and stomach. Various gastroretentive strategies, formulation difficulties, pharmacological and formulation factors influencing stomach retention, and the future prospects of GRDDS in clinical applications are all included in this review.*

**Keywords** – Controlled release, floating system, drug delivery, gastroretentive drug delivery system (GRDDS), bio adhesive, high density system

## INTRODUCTION

Innovative techniques known as gastroretentive systems for drug delivery (GRDDS) are intended to increase the therapeutic efficacy and bioavailability of medications with digestion windows in the upper gastrointestinal (GI) tract [1]. For medications that have limited stability in the stomach's acidic environment or restricted diffusion in the lower gastrointestinal system, conventional drug delivery techniques can occasionally lead to poor bioavailability [2]. In order to overcome these difficulties, GRDDS permits extended gastrointestinal retention, which is particularly advantageous for medications that are absorbed in that the stomach or adjacent the small intestinal tract [3]. The idea behind GRDDS is to keep the form of dosage in the stomach for a long time, which improves drug absorption and prolongs the therapeutic effect of the medication [4]. Rotating systems as a whole bioadhesive systems, swollen and contracting systems, a high-density infrastructure, and super porous hydrogels that are some of the methods used to accomplish gastro retention. The design, categorisation, mechanisms, and most recent developments in GRDDS are the main topics of this review [5]. Clinical uses, difficulties, and the possible future of gastro retentive mechanisms within drug delivery technology are also covered [6]. Each of these strategies offers unique benefits for different kinds of drugs and has its own methodology and applications [7].

"The layout of gastro retentive medication delivery systems (GRDDS) provides new horizons in optimizing the bioavailability of medicines for drugs with narrow consumption windows in the GI tract. GRDDS improves the curative effectiveness of drugs by maintaining a longer period of residence in the gastrointestinal tract, thereby ensuring more consistent discharge and the absorption process [8]. This review supplies an in-depth evaluation of the systems, technologies that and materials that comprise GRDDS, as well as the probable applications in medicine and boundaries of these systems [9]." "Gastro retentive systems for delivering drugs (GRDDS) have become known as an important way to improve the efficacy and safety of oral medications, in particular those alongside little solubility or unique taking in locations in the gastrointestinal system [10]. By prolonging the time period of drug entry into the intestinal tract, GRDDS may increase accessibility, reduce administering the rate, and possibly increase compliance for patients [11]. This brief overview outlines the categories, development procedures, advantages, and shortcomings of GRDDS, alongside a focus from latest developments and the eventual something of this technology at their disposal." Improved drug absorption is made possible by GRDDS, especially for medications that are mostly absorbed in the digestive tract or upper GI tract [12]. This thorough review examines the benefits, drawbacks, and potential future directions of the different types of GRDDS, such as floating, mucoadhesive, oedema, and capable of being expanded systems [13].

**Classification**

**Types of Gastroretentive Drug Delivery Systems (GRDDS)**

**Floating Drug Delivery Systems (FDDS):**

**Mechanism**

These organ systems are made capable of floating on the stomach's membrane and extend the Retention period because they are less dense than gastric fluids. A more prolonged and Efficient releasing medications in the upper part of the GI tract is made possible by drug Delivery systems that float (FDDS), which are sophisticated medicine delivering methods made.

Multiple-Unit Systems this method lowers the possibility of dose-dumping and produces an Extra consistent releasing profiles by using tiny floating particles (such as floated nanoparticles




***Figure 1*: *Mechanism of FDDS***

Or microbeads) to disperse across the digestive tract. Because of the decreased inter-subject Variation, those are frequently used. Devices for Raft-Forming these processes create a "raft" Or sticky liquid than hovers in above the stomach contents.

Raft-forming structures, as are Frequently found in antacid products, comprise substances such as sulfuric acid that combine with stomach acid to create a liquidlike raft than floating as delivers medication locally. This Is extremely helpful in curing gastrointestinal reflux disease (GERD). Devices with Hydrodynamic Balance (HBS) To guarantee that the dose forms is a weight that is that is below Stomach liquids, HBS formulations combine low-density polymers and fillers. The medicine is Kept in the GI tract on a long time by the polymer chains, which absorbed gastric juice and expand to create a buoyant weight.

**Examples**

**Effervescent Systems**

**Examples include**

Propranolol hydrochloride floating capsules containing sodium bicarbonate and citric acid; gastroretentive tablets containing sodium bicarbonate (such as ciprofloxacin FDDS); and alginate-based microspheres that release gas to form a floating gel.

**Non-Effervescent Systems**

**Examples include**

Hydrocarbon-based floating systems that use polyacrylate or HPMC polymers.

Drugs like ketoprofen in hollow microspheres or micro balloons that are buoyant due to polymers Low density floating tablets containing medications like hydrochloride verapamil.

**Uses**

Prolonged Drug Delivery these work best with drugs that have a regulated delivery. By Extending the duration of medication departure, FDDS improves treatment outcomes by Maintaining a steady level of drug in the circulation.

Decreased Taking Duration Clients frequently need smaller amounts due to FDDS's Continuous discharge, improving compliance and lessens negative reactions associated with Medication peak levels.

Better Solubility and Stability FDDS helps medications that require an acidic environment to remain viable or that have volatile in the neutral pH of the gut. Therapy of Intestinal Conditions Because FDDS allows for targeted administration of Medications in the intestines, it is beneficial in the management of belly-specific conditions Such gastritis in ulcers of the stomach, and gastro oesophageal reflux disorder (GERD).

Improved Client Adherence FDDS improves patient comfort and compliance by lowering the Amount of dosage and keeping doses inside the limits of treatment.

Enhancement of Gastro-Retentive The solutions FDDS is a component of gastro-retentive Drug delivery systems (GRDDS), which aid in the management of medications who don't Absorb well in the small bowels.

With prolonging their stay in the stomach and colon, GRDDS Serves to increase the effectiveness of such medications [14]

**Mucoadhesive Systems**

**Description**

These technologies lengthen the gastric residency period by adhering to the gastrointestinal tract lining with bio adhesive polymers. formulation that sticks to the body's mucosal lining, prolonging the amount of time a medication is at the location of digestion. This technique enables localised and prolonged medication release by bonding with the mucus layer using polymers such as hydroxypropyl methylcellulose (HPMC), carpool, or chitosan. Because it improves drug absorption and their bioavailability the MDDS is especially helpful for medications that are taken orally, nasally, gastrically, or vaginally.

**Mechanism**

To create adhesion, polymers such as glucosamine and carbon dioxide interact with the Stomach's mucous layer. By adhering to the gastrointestinal (GI) tract's mucosal lining, Mucoadhesive delivery systems for drugs provide extended medication retention and Assimilation at the application site. A mucoadhesive system gathers moisture and swells when it comes into contact with a moist Surface, such as the mucosal lining. This promotes adherence by increasing the surface area and enabling closer contact with the mucosal layer.




***Figure 2*: *Mechanism of Mucoadhesive system***

Electrostatic and Hydrogen Bonding to Increase adhesion strength, mucoadhesive polymers frequently establish electrostatic or Hydrogen bonding interactions with the charged with negative musing glycoproteins in mucus. Physical Interlocking to strengthen the mechanical attachment and lengthen the retention Period, certain mucoadhesive polymers pierce the surface of the mouth and interlock within the mucus network. Hydrophobic Interactions although less frequent than hydrogen bonding In polymers which are hydro some mucoadhesive compounds may form hydrophobic reactions With the mucus to aid in adhesion.

**Applications**

Oral Drug Delivery to improve drug uptake via the throat, the back, or the bowels, mucous Adhesive methods are frequently utilized for oral administration. Because it increases Bioavailable and decreases the amount of dose, this is especially advantageous to medications with limited absorbing windows.

Mandibular or Sub Medication Delivery Direct penetration in the circulatory system via the gut is made possible by the application of mucoadhesive Materials on the mandibular (chin) or lingual (those below the tongue) areas. Bypassing the GI System, this approach avoids the liver's first-pass metabolism and provides a quicker Medication onset.

Gastroretentive Medicine Deliveries Medicines that need pH balance or are intended to treat Gut-related disorders such ulcers and glandular sickness can stay inside the gastrointestinal tract Longer thanks to mucous adhesive system.

Nose medication distribution by enhancing holding A period of time mucous adhesive structures within the nasal passages enable improved Medication absorption across the mucosa of the nose. This may be beneficial in systematic Distribution while the treatment of ailments like allergens.

Optical Medication Deliveries Eye Drop solutions or gels with mucous adhesive systems assist medications stay on the retina for Longer, increasing drug uptake and efficacy in healing disorders as dry vision, conjunctive and Cataracts [15].

**Swelling and Expanding Systems**

**Description**

Expanding and Swelling In order to linger longer in the gastrointestinal tract and release the drug gradually, the routes of administration are made to enlarge when they come into touch with gastric juices. These methods make use of hydrophilic polymers, such as sodium alginate, polyacrylates, or HPMC, which absorb water and cause the dosage form to expand and swell. The larger size prolongs the period that the medication is retained in the stomach and improves absorption by preventing the amount taken in passing through the throat sphincter.

These systems work by using super-porous or bruising polymer compounds that expand in size, keeping the formulation in the stomach.

**Mechanism**

They are effective for medications with limited absorption windows, like antiviral medications Like acyclovir. In order to stay in a specific region of the gut (GI tract) for a long time, swollen and extending delivery systems for drugs are made to enlarge after injection. Polymers Hydration The formulation's polymeric acquire water and start to rehydrate once the supply System comes into contact with the body's fluids. The polymers system becomes pliable and prepared for growth as a result of the earliest Hydration. Expansion Polymers will experience swollen as a result of liquid uptake following Hydration.




***Figure 3*: *Mechanism of Swelling and Expanding System***

When subjected to humidity, hydrophilic polymers, those including sodium alginate, Carpool, or hydroxypropyl methylcellulose (HPMC), can expand considerably. Stomach delay Is prolonged because of the enlargement, which makes the system bigger and frequently unable To move swiftly along the gut. Gels Layer Formation polymers surround the medication's core in a jelly-like layer as they grow. The protective role within the gelatin layer regulates the Medication release rate. The kind of polymeric material, molecular mass, and connecting strength are some of the Variables that affect that layer's depth and uniformity. Limited Medication Release means that Drug diffusion is facilitated by the gel layer that forms upon inflation.

**Applications**

In many therapeutic applications, swelling and extending drug delivery mechanisms are Employed, especially for medications that benefit from regulated release and extended stomach Retention. Gastroretentive Drug Delivery for medications that are mostly absorbed in the upper Gastrointestinal tract, swelling and expanding methods work well.

They help medications with Limited absorption windows or medicines that work better in an acidic environment through Broadening in the stomach and preventing an early transit to the intestines. Controlled-delivery Formulations these methods enable a steady, extended delivery of medications over an Extended period of time.

Controlled-Release Formulations these systems allow for a consistent, prolonged release of Drugs over time. This is beneficial for medications requiring steady plasma concentrations, Reducing fluctuations, side effects, and the need for frequent dosing.

Treatment of Localized Gastric Conditions: Swelling systems can deliver drugs directly to the stomach, making them Effective for treating conditions such as peptic ulcers, gastritis, and Helicobacter pylori Infections. This helps in targeting the drug action at the site of disease while minimizing Systemic side effects.

Extended Therapy for Chronic Conditions for chronic conditions like diabetes or hypertension, Swelling and expanding systems offer a way to deliver drugs over an extended period, improving patient compliance and maintaining therapeutic levels with fewer doses.

Delivery Of Drugs with Poor Solubility these systems can improve the bioavailability of drugs that are Poorly soluble in the intestines but more soluble in the acidic environment of the stomach by Retaining the drug there for a longer time.

Paediatric and Geriatric Medicine reduced dosing frequency from controlled-release swelling Systems can improve adherence in populations that may struggle with regular medication Schedules, such as children and the elderly. Swell or increase significantly when they come into interaction with gastric fluids, stopping them from travelling through the pylorus [16].

**High-Density Systems**

**Mechanism**

High-density mixtures settle in the gut actually than floating in the air aiding prolonged Gastrointestinal residence. Use of A high level of Materials these systems use high-density Materials, including titanium dioxide, zinc oxide, barium sulphate, or iron powder, to attain Adequate density, which adds weight to the system. For the digestive system to conquer the Natural velocity of gastric contents and stay in the stomach, a density of in excess of 2.5 g/cm³ Is usually needed. Sinking in the Stomach rather than flying or traveling to the intestines after Ingestion, a high level of structure lowers toward the bottom within the stomach.

It remains Confined to the lower stomach area due to gravity and the system's density. Sensitivity to Gastric Emptying the system's high density helps it stay in the stomach by preventing the usual Gastric emptying process. Gradual Pharmaceutical Release High-density systems frequently include controlled drug Release built in, which enables the medicine to be released gradually into the stomach.




***Figure 4*: *Mechanism of High-density system***

For Medications that benefit from gradual, prolonged release, this is perfect since it keeps the Bloodstream's drug content steady. Improved Stomach Absorption High-density systems are Particularly helpful for medications that metabolize better in the stomachs or upper Gastrointestinal tract's acidic environment because they remain in the stomach for a longer Period of time. For the gastroretentive delivery of medications that require a controlled release are meant to operate locally in the stomach, high-density system.

**APPLICATION**

HDDS are formulations that use high-density materials to improve drug delivery, usually for controlled, prolonged, or targeted release applications. By increasing patient compliance, reducing adverse effects, and maximizing medication absorption, these mechanisms can improve treatment outcomes.

Improved Absorption of Drugs HDDS can improve the digestion of poorly soluble medications by regulating the location and rate of drug release in the GI tract. By keeping the medication in the proximal areas of the GI tract, where absorption is higher, high-density formulations can increase bioavailability.

Localized Infection Management Helicobacter pylori infections and other illnesses that are restricted to the small intestines or stomach can be effectively treated using high-density systems. They can reduce systemic side effects by directly delivering larger concentrations of penicillin or other medicines to the afflicted location.

Delivery of Vaccines Orally Vaccines can be administered orally using high-density systems, which target specific areas such as the intestinal Peyer's patches to boost immunity. This strategy can increase stability.

Regulated Hormone or Enzyme Delivery By offering a controlled release that reduces exposure to degrading enzymes, HDDS can administer proteins or enzymes that are susceptible to breakdown in the GI tract. For polypeptide and protein medications, which are frequently volatile in the GI environment, this application is advantageous.

Treatment for Cancer Additionally, HDDS can be used to treat cancer, especially digestive tract cancers. By helping to concentrate chemotherapy medications at the tumor site, the thick formulation may improve efficacy and lessen systemic side effects.

**Examples**

The Dense pellets, pills [17].

**Magnetic Systems**

**Mechanism**

Drug-carrying are guided and held in place at a precise location within the human being by magnetic forces in magnetism systems for delivering medicines. This method improves medicine efficacy, minimizes unwanted effects, and achieves targeted distribution. Integration from Magnetism Parts Iron dioxide (Fe3O4) and other magnetic compounds are embedded into biodegradable carriers for drugs, such as liposomes, polymer compounds, or tiny spheres, to create magnetism drug transport providers, which are frequently formed out of nanomaterials. The vehicle can be guided to a specific location thanks to these magnetism particles' response to magnetic fields from outside.[18]

Application of an External Magnetic Field An electromagnetic field or an external magnet is placed close to a goal location (such as a tumor or particular organ). By drawing the magnetized carriers of medicines to a specific spot, the field of magnets stops their dispersing to non-targeted locations and enables then to focus that the chosen point.

Localization and Persistence at Target Site That drug-loaded carrier can be kept at their intended place for an extended amount of time by varying the magnetic field's strength and alignment. By increasing accumulation of drugs at the target's site, this reduces the exposure of non-target tissues and allows for a larger local level.




***Figure 5:*** *Mechanism of Magnetic system*

Control Drug Release The medication is progressively discharged from the carrier over time in several magnetic devices that are built for controlled release. In particular systems, heat is produced by a magnetic field that is alternating. This can cause release of drugs (a process known as magneto thermally-induced releasing) or even cause hyperthermia, which may destroy cancer cells.

Improved Neuronal Uptake Drug carriers' nearness to the target site as a result of magnetic retention may increase the likelihood of uptake by cells.

This is particularly advantageous when treating cancer, as clinical outcomes can be improved by high medication levels at tumor cells. Decreased Overall Side Affects: By minimizing medication dispersal over the body, magnetic targeting lowers systemic levels and adverse effects.

**Examples**

Magnetic microspheres [18].

**Anatomy Of Stomach**

An intricate organ, the stomach is essential to digesting. Its tasks are supported by a variety of areas, layers, and specialised cells that make up its anatomy. Here is a detailed examination of the stomach's five main anatomical features:

**Regions of the Stomach**

The stomach's cardia, the fundus, muscle (corpus), antrum is, and pylorus are its five primary sections.

**Cardia**

The region where food passes from the oesophagus into the stomach. The junction of the oesophagus and stomach is known as the cardia. It has the oesophageal sphincter's lower (LES), an engagement ring of muscle that stops acid reflux by preventing stomach acid from flowing backward into the oesophagus. This area does not generate a lot of digestive secretions and is mostly used as an entrance.

**Fundus**

The dome-shaped structure that holds unprocessed food and gas is called the fundus. The fundus the rounded, dome-shaped part of the stomach that rises close to the diaphragm is called the fundus. It occasionally momentarily traps undigested food and stores the gasses created during digestion. In comparison to the remainder of the stomach, this area frequently has a somewhat higher pH.

**Body**

The largest area where digestion and mixing take place. The majority of the processes of digestion occur in this biggest, centrally positioned area of the stomach. The gastric glands in this region emit hydrochloric acid (HCl) and digestive enzymes (such as pepsinogen), which produce the acidic environment required for food breakdown and enzyme activation. Parietal lob cells, chief cells, mucosal cells, and cells known as G cells are also found in the stomach's body, and they support both protection and digestion.

**Antrum**

The lowest portion that controls emptying and grinds food. The bottom portion of the stomach serves mainly as a grinding and mixing chamber because it is smaller than the rest of the stomach. Powerful contractions of the muscles Here, food particles are broken down and combined with stomach secretions to create chime. The type of hormone gastrin, which promotes acid generation and motility, is released by G cells in this area.




***Figure 6*: *Anatomy of Stomach***

**Pylorus**

The valve that regulates food flow to the digestive tract is called the pylorus.

Each area plays a distinct part in the chemical and mechanical breakdown of food [19]. Pylorus The duodenum, the first segment of the small intestine, is connected to the pylorus, the stomach's last segment. Only food that is partially digested can pass through at an established pace for more digestion and absorption because of the pyloric sphincter, which is a muscle valve that controls the release of chyme that is into the small intestine.

**Layers of the Stomach Wall**

**Description**

There are four main layers that make up the stomach wall

**Mucosa**

The stomach's innermost layer, known as the mucosa, is lined with Epithelial cells, which are found that secrete mucus to prevent self-digestion. The deepest layer, which is made up of the muscularis mucosae, lamina propria, and epithelium. Specialized cells found in the epithelium include mucous cells, which generate mucus to shield the gastrointestinal lining from acidic damage, chief cells, which release a substance known as the precursor to pepsin, and parietal cells, which produce Hydrochloric and an intrinsic factor for the vitamin B12 absorption. Gastric pits are deep pits in the mucosa that extend into the gastric glands, which are in charge of secreting the ingredients of gastric juice.

**Submucosa**

Blood veins, nerves, and tissue connections support the mucosa in the submucosa. The submucosa is a layer of connective tissue that houses nerves, lymphatics, and blood arteries. In addition to providing the mucosa with oxygen and vital nutrients, it aids in the absorption of nutrients that have been digested.

**Muscularis**

The muscularis, which aids in churning food, is made up of three layers of muscle are longitudinal, circular, and oblique. The long-term, circular, and transverse muscle layers comprise the muscularis layer. The stomach can mix food with fluid from the stomach and break it into numerous smaller pieces because to the intricate churning and peristaltic activity made possible by these muscle layers.

**Serosa**

The outermost layer, or serosa, is a thin barrier that lessens contact with the organs around it. the outermost covering which is covered by the peritoneal cavity and is made up of connective tissue. The stomach can move and develop without rubbing against nearby organs because to this layer's protective covering and structural support.

**Function**

These layers cooperate to protect the stomach lining, produce bodily movements for food disintegration, and secrete digestive enzymes.

Meals Preservation Meals may be stored in the gut for a long period before being progressively released through the intestinal tract. Physical Ingestion Feed and digestive juices are mixed together and broken into many tiny pieces by the spasms of the stomach's muscles.

Biochemical Ingestion Although stomach lipase starts metabolizing of calories, the presence of acid stimulates pepsin and destroys structures. Security The fluid produced by the gut walls serves as a defence from the enzymes used in digestion and its unique ph. Numerous germs and diseases found in food are also eliminated by the ph atmosphere.

Chemical Production and Oversight The intestine coordinates digestion by interacting with different organs of digestion and controlling its individual metabolism via secretions such as somatostatin and gastrin [20].

**Gastric Glands and Cells**

The stomach's gastric glands are home to a variety of specialized cell types, including:

**Parietal cells**

Hydrochloric acid is secreted by parietal cells, which are essential for digestion and establishing an acidic environment. Found in the retinal and physique such cells emit an intrinsic component, that is necessary for the tiny intestines to absorb vitamin B12, and the acid hydrochloric acid, which produces an acidic atmosphere (with a pH 1.5–3.5) promotes the breakdown of proteins.

**Chief Cells**

Generate the inactive enzyme pepsinogen, which the stomach converts to pepsin to break digest proteins. Found within the retinal and physique, these cells create the hormone peps an inert enzyme that starts the breakdown of proteins by turning to this enzyme in acidic conditions.

**Mucous Cells**

Create mucus to shield the lining of the stomach. The mucous cells are present all across the gastrointestinal interior, but particularly close to the outer layer. These release fluid, which covers and shields the gastrointestinal lining against proteins and water which would otherwise break it down on its own.

**G Cells**

Release the hormone gastrin, which promotes the generation of acid. Found within the antrum, these little cells release a hormone called gastrin, causing cells in the parietal region to emit more acid and speeds up the movement of the stomach.

Both chemical and mechanical digestion are carried out by the intricate organ known as the stomach. It can break down food, defend against self-digestion, and control the rate of digestion to guarantee adequate nutritional absorption because to its cells with particular abilities and multilayered structure. Maintaining effective digestion and making sure the surplus food goes through processing in a safe and regulated way depend on the complex processes of the stomach [21]

**Blood Supply**

The coeliac trunk's branches provide a plentiful blood flow to the stomach. The coeliac trunk, a large artery that emerges into the aorta in the abdomen, provides the majority of the flow of blood to the stomachs. The digestive and gastroepiploic veins are a vast network of branching that surround the stomach.

**Left gastric artery**

The upper portion of the stomach is supplied by the left gastric artery. One of the coeliac trunk's straight branches. Provides the gastrointestinal cardia and the top portion of the lesser curve. Creates connects, or interactions, across the curve that is smaller with the correct stomach vein.

**Right gastric artery**

The stomach's lower curvature is supplied by the right gastric artery. The standard abdominal vein, whose likewise emerges out of the intestinal body, has an extension. Provides the gut's lower section of its smaller curve. Connections across the shortest bend involving the left side stomach vein.

**Gastroepiploic arteries**

The larger curvature is supplied by the gastroepiploic arteries. Originates via the normal abdominal artery's sector, the gastroduodenal vein. Provides the gut's interior with its larger curve. Develops connections across the larger curvature into the left-hand gastroepiploic vein [22].

**Nerve Supply**

**Description**

The immune system provides the nerve supply to the stomach. The neural supply of the stomach is essential for controlling its many intricate processes, such as reflexes, secretion, and motility. Both the gastrointestinal nervous system (ENS) and the self-regulating nervous system (understanding and parasympathetic nerves) innervate the stomach. These systems work together to make sure the stomach reacts to food intake in the right way, modifies the digestive process, and controls pain or discomfort.

**Vagus nerves or parasympathetic nerves**

Increase gastric motility, peristalsis, and enzyme production to promote digestion. In the stomach, the nervous system known as the parasympathetic system mainly promotes the release of enzymes, the secretion of acid, and the contraction of muscles to mix food. The vagus nerve serves as the principal parasympathetic stimulus to the stomach, profoundly affecting digestion. As it approaches the stomach, the left vagus nerve transforms into the anterior vagal trunk after descending anteriorly over the oesophagus. The posterior part of the vagal trunk is formed when the right vagus nervous system descends.

Enhanced Gastric The ability to move: Vagal stimulation encourages the stomach's muscles to contract, which helps mix and churn food. Increased Gastric Secretions: Acetylcholine released by vagal fibers causes principal cells to release the enzyme peps and parietal cells to release hydrochloric acid. Hormone production: Vagal stimulation causes the antrum's G cells to release gastrin, also which in turn encourages the production of acid and the motility of the stomach.

**Sympathetic Nerves**

Reduce gastric secretions and inhibit stomach activity. In the stomach, the adrenal glands has an inhibitory function. It contributes to the experience of gastrointestinal pain, decreases gastric motility that secretion, and redirects blood flow towards the stomach during stress. Origin and Route: Segments T5 through T9 of the spinal cord are the source of the sympathetic fibers that supply the stomach. These fibers pass through the celiac ganglion, a crucial component of the celiac plexus that is situated close to the stomach, via the larger splanchnic nerve and synapse.

Reduced Gastric Motility Prevents the stomach wall's smooth muscles from contracting, which lessens gastric mixing during emptying. Vasoconstriction: Reduces blood flow to the stomach mucosa and digestive secretions by narrowing the stomach's blood vessels. Pain Sensation The brain's central nervous system receives pain feelings from the stomach thanks to sympathetic innervation. Inflammation, swelling, or distension are common causes of stomach pain, which is typically experienced as cramps or blistering feelings.

**Function**

By boosting activity during meal intake and lowering it during stress, this dual innervations aids in controlling stomach functions according to the body's needs [23].

**Gastrretentive Dosage Form [GDF]**

Advanced drug delivery methods called gastroretentive forms of administration (GRDFs) are made especially to keep medications in the stomach for a long time. They promote drug absorption bioavailability, and controlled release by extending gastric retention, particularly for medications with a limited window for absorption in the GI tract or upper portion of the tiny intestines. This is a thorough analysis of GRDFs that covers their types, workings, benefits, drawbacks, and uses.[24]

**Need for Gastroretentive Dosage Forms**

Because of a limited window for absorption in the GI tract or upper small intestine, several medications greatly benefit from prolonged gastric retention problems with stability in the small intestine's alkaline pH stomach-specific therapeutic effect. Short Uptake Opening Increasing the length of time a medication is in the GI tract or upper smaller intestine improves uptake because some medications are exclusively taken there. [25]

Increased Solubility in Gastric pH If a medicine is kept in the stomach for an extended amount of time, it may have better bioavailability since it tends to be soluble in acidic environments, such as the GI tract. Security Some medications are safe in the stomach's acidic conditions but unstable in the intestines' pH value. Longer retention of gastric acid is associated with greater efficacy for medications designed for specific action on the digestion, such as medications as antibiotics treating H. pylori infections. higher bioavailability of drugs. Increased medication effectiveness as a result of extended release. Greater compliance from patients and a decrease in the number of doses. Reduced side effects because the medication stays confined.

**Examples**

Medications include furosemide, amoxicillin, metformin, and certain antibiotics (such as tetracycline), which exhibit enhanced efficacy when prolonged in the stomach [26].

**Advantages of Gastroretentive Dosage Forms**

**Enhanced Bioavailability**

GRDFs help medications with a limited absorption window be better absorbed by staying in the stomach.

**Focused Delivery**

To maximize benefits and minimize adverse effects, GRDFs offer focused delivery for medications that need a local action in the stomach.

**Improved Patient Compliance**

GRDFs help patients adhere to treatment more effectively by lowering the frequency of doses and increasing efficacy [27].

**Medications for H. pylori**

Antibiotics that target the bacteria that causes peptic ulcers, H. pylori, are more efficient when taken for an extended period of time in the stomach [28].

**Antacids and Anti-Ulcer Drugs**

Long-term action in the stomach helps medicines such ranitidine and famotidine effectively neutralize acid and treat ulcers.

**Antidiabetic medications**

Due to their limited absorption window, medications such as metformin are more effective with long-term stomach retention.

**Cardiac Drugs**

In order to sustain beneficial effects over time, medications such as propranolol and verapamil need to be released under controlled conditions [29].

**Disadvantages of gastroretentive dosage form**

**Variable Gastric Conditions**

Drug release and levels of absorption might be unpredictable due to variations in gastric emptying time, which can be influenced by age, disease, and food intake.

**Limited to certain drug**

GDFs are only appropriate for medications that have absorption apertures in the stomach or large intestine and are durable in gastric acid. GDFs should not be used with medications that are unstable at acidic pH values or that are poorly soluble in gastric juices.

**Risk of dosage Dumping**

The medicine may be released too quickly if the system is unable to hold in the GI tract and moves into the colon too soon, which could result in dosage dumping and possible adverse consequences [30].

**Formulation and Manufacturing Complexity Specialized Technology**

Gas-generating representatives, bio adhesive polymers, and expandable matrices are just a few examples of the cutting-edge materials and technology needed to formulate GRDFs. As a result, manufacturing becomes more expensive, complex, and potentially unpredictable [31].

**Quality Control**

Drug release as well as retention must be consistent, however because of GRDFs' intricate construction, it can be difficult to guarantee consistent performance across batches.

**Small Patient Groups Unsuitable for Individuals with stomach abnormalities**

The efficacy and safety of GRDF may be limited for patients who have stomach procedures (such as gastric bypass), motility abnormalities, or gastroparesis due to their erratic performance.

**Unsuitable for Elderly and Paediatric Patients**

Due to variations in pH levels and stomach motility, the efficacy and absorption of GRDFs may change between paediatric and geriatric individuals [32].

**Limitations of Gastroretentive Dosage Forms**

For medications that need prolonged gastric retention, gastroretentive form of administration (GRDFs) provide a number of benefits, but they also have certain drawbacks. Their effectiveness, suitability, and dependability in medication delivery may be impacted by these constraints. [33]

**Dependency on Gastric Conditions**

GRDF performance may be impacted by changes in food consumption, pH, and gastric motility.
Restricted to Substances with Particular Features.

Requirement for pH Stability is a GRDFs work best with medications that are robust and efficient in the stomach's acidic environment. This kind of delivery is inappropriate for medications that become volatile at low pH or lose their effectiveness in acidic environments (such as some antibiotics and peptides).

**Suitability for Particular Drugs Only**

GRDFs work best for medications that are mostly absorbed in the GI tract or upper bowel and that have a steady pH in the stomach. Limitation on Absorption Window: GRDFs work best for medications that are mostly absorbed in the GI tract or upper portion of the small bowel. Prolonged gastric retention is not beneficial for medications that must be absorbed in the colon or ileum, which are lower portions of the gastrointestinal tract.

**Risk of Dose Dumping**

In certain situations, certain formulations may not work as intended, causing the whole dosage of the medication to be released all at once. The amount of medication that a GRDF can provide is restricted by the stomach's volume and capacity. Large dosage forms may be necessary for high dose medications.[34]

**Limitations Particular to the Patient**

Unsuitability for Individuals with Gastric Disorders: Individuals who have partial gastric resections, anatomical alterations in the stomach, or disorders of gastric motility (such as gastroparesis) may have unexpected gastric retention times when using GRDFs. As a result, GRDFs may not be as appropriate for these individuals due to irregular drug release and absorption.

**Restricted Use in Elderly and Paediatric Patients**

It can be difficult to obtain sustained gastric retention in pediatric and elderly patients due to the considerable effects of age on pH levels and stomach motility. Furthermore, several GRDF systems may make older individuals and youngsters more prone to discomfort or negative reactions [35].

**Merits and Demerits of Gastroretentive Drug Delivery System**

There are benefits and drawbacks to gastro-retentive medication delivery systems (GRDDS) that affect their efficacy and therapeutic use. A thorough evaluation of the benefits and drawbacks of GRDDS is provided below, along with reading recommendations.

**Merits of GRDDS**

**Enhanced Bioavailability for Medicines with a Limited Window of Absorption**

GRDDS increases the bioavailability of medications that are mostly absorbed in the GI tract or the proximal portion of the small intestinal tract by extending their gastric retention period. For medications with few absorption sites, GRDDS can greatly enhance therapeutic results by keeping the medication in the stomach for a longer period of time [36].

GRDDS eliminates the need for repeated dosage by enabling regulated or sustained release. Patients may take their medications less frequently, which may result in better treatment outcomes and increased adherence, particularly for chronic illnesses [37].

**Drug Action in the Stomach**

Drugs that must function local in the stomach, like antibiotics for intestinal infections or medications for gastric ulcers, benefit from GRDDS.

Better local action, fewer side effects that are systemic and increased efficacy can result from concentrating the medication in the stomach [38].

**Prevention Degradation in the Intestines**

In an alkaline condition of the intestines, certain medications are fragile or poorly absorbed. By keeping the medication in the stomach's acidic environment, GRDDS helps stop it from breaking down too soon. A more consistent and long-lasting medication release is guaranteed by this stability [39].

**Enhanced Solubility Basic Drugs**

The stomach's acidic environment makes weakly basic medications more soluble and increases absorption. For medications with solubility-dependent absorption, this may result in improved therapeutic effects [40].

**Demerits of GRDDS**

**Gastric pH and Food Presence**

Meals in the stomach and gastric pH can affect how well GRDDS work, particularly floating systems. For some systems to stay afloat, particular pH levels or a stomach full of food are necessary. Unpredictable stomach retention periods and irregular drug release can result from variations in pH with food intake [41].

**Risk of Gastric Irritation**

The gastric mucosa may become irritated if certain medications are kept in the stomach for an extended period of time, particularly if they have ulcer genic qualities.

This could make patients uncomfortable and decrease their compliance, especially with medications that need large dosages [42].

**Limited Suitability for High-Dose Drugs**

Due to size restrictions that may result in discomfort or a quick travel out of the stomach, GRDDS are typically less appropriate for medications that call for high dosages.

This restriction limits GRDDS to medications with low dosages or high potencies at lower dosages [43].

**Variation in Gastric Emptying Rate Among Individuals**

The retention and efficacy of GRDDS are impacted by the broad variations in gastric emptying rates caused by age, health, and body posture.

In certain cases, these differences may result in irregular medication release and decreased bioavailability [44].

## CONCLUSION

A promising method for enhancing the metabolism and therapeutic effectiveness of medications with constrained absorption windows in the upper part of the gastrointestinal tract is the use of gastroretentive drug delivery systems, or GRDDS. GRDDS are particularly helpful for medications that have particular solubility, equilibrium, or local action needs in the stomach because they increase patient compliance and allow for improved control over the release of substances by prolonging the gastric retention time. However, the presence of food, pH fluctuations, and stomach motility can all affect how well GRDDS works, making it difficult to administer drugs consistently. Additional challenges are presented by dangers such as possible stomach discomfort, restrictions on handling high-dose medications, and increased production costs. Continuous improvements in design and materials continue to increase the reliability of GRDDS, although patient-specific aspects must still be carefully considered for the best results.

## REFERENCES

1. Pawar V.K, Kansal S, Asthana S, Industrial Perspective of Gastroretentive Drug Delivery Systems Physicochemical Biopharmaceutical Technological and Regulatory Considerations, Journal of Expert Opinion on Drug Delivery,2017:14(9):1191-1205.
2. Mandal U.K, Chatterjee B, Sanjyoti F.G, Gastroretentive Drug Delivery Systems Asian Journal of Pharmaceutical Science,2016:11(5): 575-584.
3. Panakanti R, Narang, Impact of Excipient Interactions Drug Bioavailability from Solid Dosage Forms, 2017:2(3) 273-310.

4. Chordiya M, Gangurde H, Borkar V, Technologies, Optimization, and Analytical Parameters in Gastroretentive Drug Delivery Systems, Journal of Current Science, 2017:112(5): 946-953.
5. Goud, Pandey V.P, Gastroretentive Drug Delivery System, International Journal of Pharmaceutical Biological Science,2016:6(3): 158-165.
6. Dhole A.R, Gaikwad P.D, Bankar V.H, Pawar Floating Multiparticulate Drug Delivery System International Journal of Pharmaceutical Science Revolution and Research,2017:6(4): 205-211.
7. Tiwari S, Batra N, Oral Drug Delivery System American Journal of Life Science,2017; 14(2): 27-35.
8. Bala R, Khanna S, Pawar P, Arora S, Orally Dissolving Strips New Approach to Oral Drug Delivery System, International Journal of Pharmaceutical Investigation,2017:3(2): 67-76.
9. Jassal M, Nautiyal U, Kundlas J, Singh D, Gastroretentive Drug Delivery System, Indian Journal of Pharmaceutical Biology Research, 2015: 3(1): 82-92.
10. Singh B, Kim K.H, Floating Drug Delivery Systems an Approach Oral Controlled Drug Delivery Via Gastric Retention, Journal of Control Release,2017:63(3): 235-242.
11. Tomar A, Upadhyay A, Gupta S.K, Kumar S, Gastroretentive Drug Delivery System Current Approaches and Advancements, Journal of Current Research Pharmaceutical Science,2019:9(1): 12-16.
12. Shukla M, Mishra S.K, Verma A, Floating Drug Delivery Systems Approach for Controlled Release Drug Delivery Via Gastric Retention, Journal of Pharmaceutical Science Research, 2018:10(6): 1519-1528.
13. Badoni A, Ojha A, Gnanarajan G, Kothiyal P, Gastroretentive Drug Delivery System, Journal of Pharmaceutical Innovation,2012:1(8): 13-22.
14. Yenumula N, NetteKallu T, Types of Floating Drug Delivery Systems, Indo American Journal of Pharmaceutical Science, 2016: 3(6):682-687.
15. Flavia L, Alexie M, Development of Mucoadhesive Thio Carboxymethyl Cellulose for Application in Buccal Delivery of Drugs their Delivery, World Journal of Pharmacy and Pharmaceutical Science, 2016:7(2):63–71.
16. Johnson R, Kumar H,Gastroretentive Drug Delivery Systems and their Applications, International Journal of Pharmaceutical Technology, 2021:55(5): 745-762.
17. Smith J, Liu, Comprehensive Gastroretentive Drug Delivery Systems, Journal of Pharmaceutical Sciences, 2023:115(7): 1234-1250.
18. Soni S, Soni D, Gastroretentive Drug Delivery System Mechanisms and Applications, Asian Journal of Pharmaceutical Sciences,2019: 14(4):391-408.
19. Patel A, Brown K, Advances in Gastroretentive Drug Delivery Systems a Comprehens Journal of Drug Development and Industrial Pharmacy,2022: 48(9):1137-1155.
20. Kumar M, Johnson R, Gastroretentive Drug Delivery Systems and their Applications, International Journal of Pharmaceutical Technology,2021: 55(5): 745-762.
21. Deshpande, Shah N. H, Rhode C, Development of A Novel Controlled-Release System for Gastric Retention, Journal of Pharmaceutical Research, 1997:14(6):815-819.
22. Groning R, Heun, Oral Dosage Forms with Controlled Gastrointestinal Transit, Journal of Drug Development and Industrial Pharmacy,2019:15(6-7):1053-1067.
23. Gray H, Lewis, Gray's, Anatomical Basis of Clinical Practice, Churchill Livingstone,2018:5(4):10-15.
24. Johnson, Physiology of the Gastrointestinal Tract, New York,2018:6(3)34-40.
25. Boron, Boulais, Medical Physiology, Saunders ,2016:3(2):10-16.
26. Netter F. H, Atlas of Human Anatomy, Saunders,2014:3(1):25-30.

27. Gray H. Lewis, Gray's Anatomy the Anatomical Basis of Clinical Practice, Fortieth, Churchill Livingstone, 2017:6(4):23-26.
28. Streubel, Siepmann, Bodmeier, Gastroretentive Drug Delivery Systems, Journal of Expert Opinion on Drug Delivery, 2016: 3(2): 217-233.
29. Deshpande, Shah, Malick, Development of Novel Controlled-Release System for Gastric Retention, Journal of Pharmaceutical Research, 2017:14(6):815-819.
30. Jain, Chaturvedi, Recent Advances in Gastroretentive Drug Delivery Systems, Asian Journal of Pharmaceutical and Clinical Research,2011: 4(1): 1-10.
31. Pawar, Kansal, Garg, Awasthi, Gastroretentive Dosage Forms with Special Emphasis on Floating Drug Delivery Systems, International Journal of Pharmaceuticals, 2011:415(1-2):133-143.
32. Nayak, Maji, Das, Gastroretentive Drug Delivery Systems Asian Journal of Pharmaceutical Clinical Research, 2015:3(1):2-10
33. Streubel, Siepmann, Bodmeier, Gastroretentive Drug Delivery Systems, Journal of Expert Opinion on Drug Delivery ,2015: 3(2):217-233.
34. Deshpande N.H, Shah, Rhodes, Malick, Controlled Release Drug Delivery Systems for Prolonged Gastric Residence, Journal of Drug Development and Industrial Pharmacy, 2017:23(6):531-539.
35. Bardonnet, Faivre, Pugh, Piffaretti, Gastroretentive Dosage Forms Special Case of Helicobacter Pylori, Journal of Controlled Release,2016: 111(1-2):1-18.
36. Awasthi R, Kulkarni, Decades of Research in Drug Targeting Using Gastroretentive Drug Delivery Systems for Anti-Infective Therapy, Journal of Current Drug Delivery, 2016:13(5):632-646.
37. Klausner, Lavy, Friedman, Hoffman, Expandable Gastroretentive Dosage Forms, Journal of Controlled Release,2013: 90(2):143-162.
38. Garg, Sharma, Gastroretentive Drug Delivery Systems, Journal of Pharmatechnology, 2013:4(1):160-166.
39. Groning, Heun, Oral Dosage Forms with Controlled Gastrointestinal Transit, Journal of Drug Development and Industrial Pharmacy,2014: 10(4):527-539.
40. Deshpande, Shah, Rhodes, Controlled Drug Release, Journal of Controlled Release,1997: 45(1):15-23.
41. Sakshi Wale, Rohan More, Pratiksha Tavate, Yogesh B. Raut, Sanjay K. Bais, Unlocking Nature's Pharmacy Power of Herbal Medicine In Modern Healthcare, International Journal of Pharmacy and Herbal Technology 2024:2(2):1598-1602.
42. Amol V. Pore, Sanjay K. Bais, Vaibhav Ghutukade, Recent Advancement in Herbal Technology, International Journal of Pharmacy and Herbal Technology 2024:2(1):428-439.
43. S. R. Mane, Sanjay K. Bais, Aditya Mali, Green Chemistry and Catalysis, International Journal of Pharmacy and Herbal Technology 2024:2(1):418-427.